Pfizer launches OTC Nexium; Celgene appears to gain in patent hearing; Adcock plots major restructuring;

@FiercePharma: Top-read Tues: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing. Story | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Story | Follow @TracyStaton

@EricPFierce: ICYMI: Takeda now 5 for 6 in defending Actos cases at trial. Article | Follow @EricPFierce

@CarlyHFierce: GSK officially under investigation by Britain's Serious Fraud Office. Release | Follow @CarlyHFierce

> Pfizer ($PFE) rolled out Nexium24HR, its over-the-counter version, under a license deal with the prescription version's maker, AstraZeneca ($AZN). Whether the OTC med will face generic Nexium competition isn't clear, thanks to the Indian drugmaker Ranbaxy Laboratories. Report (reg. req.)

> Celgene ($CELG) appears to have come out ahead in an initial hearing over its Revlimid patent fight with the would-be copycat drugmaker, Natco Pharma. Report

> Adcock Ingram, which spurned a takeover attempt by CFR Pharmaceuticals, posted a first-half loss on deal-cost writedowns; its new CEO plans a wholesale restructuring of the business. Report | Report

> India's Aurobindo Pharma has made its founder, P.V. Ramaprasad, a billionaire, as its shares have more than tripled over the past year. Report

> Actavis ($ACT) confirmed that AstraZeneca ($AZN) sued for patent infringement after the generics maker filed for FDA approval of its knockoff version of AZ's diabetes treatment Onglyza. Report

Medical Device News

@FierceMedDev: Volcano grabs ArtheroMed for up to $130M. News | Follow @FierceMedDev

@VarunSaxena2: RT from FierceMedicalDevices: FDA says recalled pediatric nasal prongs potentially deadly. Story | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: $PFE, $FRX and $LLY dominate top 10 ranking of psych meds. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Biosensors picks a new CEO as revenues slide. Story

> Spectranetics offers up $230M for cardio balloon maker AngioScore. More

> China gives its official thumbs up to Sorin-MicroPort partnership. Report

Biotech News

@FierceBiotech: Turn on, tune in, tweet out for upcoming chat on CAR-T with @JohnCFierce & @PennMedicine's David Porter. #FierceASCO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fast biotech -- Upstart Spark grabs a $73M round to back rapid expansion, PhIII study - gene therapy. News | Follow @JohnCFierce

@DamianFierce: Per @Real_MNA, $SYK not bidding on $SNN but reserves right to do so within 6 mths. Palpable excitement for more UK takeover confusion. | Follow @DamianFierce

@EmilyMFierce: Pace of new MERS infections in Saudi Arabia slows to four a day. More from Reuters | Follow @EmilyMFierce

> Bayer taps Dutch antibody specialist for biologics discovery. More

> Slumping Array aligns with Biogen on early autoimmune R&D. Article

> Valeant dials up its Allergan bid and throws in some R&D promises. Story

> Troubled Trimel touts effect of its female sexual disorder drug Tefina. Report

Drug Delivery News

> PolyTherics picks up Canadian delivery tech for targeted cancer treatment. Article

> Stentys releases data, says CE mark for sirolimus-eluting stent likely. More

> 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story

> Mannkind: Approval of inhaled insulin drug around the corner. Report

> Swiss team develops imaging technique to aid drug delivery in constricted blood vessels. Item

Diagnostics News

> FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug. News

> Roche, undaunted by reimbursement cutbacks, sees no need for Dx price reductions. Report

> In a first, Immucor wins FDA approval for a blood transfusion molecular Dx test. More

> iRhythm has CE mark in sight for arrhythmia Dx patch. Article

> Chinese scientists create viable paper Dx for hepatitis C virus. Story

Pharma Marketing News

> Sanofi, Lilly hook up to switch impotence remedy Cialis to OTC. Story

> J&J launches 'quantified self' app to game patients into better behavior. Article

> Takeda's colitis med Entyvio wins European OK on heels of FDA's approval. Item

> Sanofi's new MS med scores a spot on U.K.'s NHS formulary. More

> Pfizer, Forest and Lilly dominate top 10 ranking of psych meds. Story

> Got a problem, doc? In Eli Lilly's brave new sales world, that's a plus. Article

And Finally... Meditation could be the treatment for bad investment decisions. Report

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.